Cladribine Based Salvage Chemotherapy

A Phase II Study of the Efficacy and Pharmacogenomics of Cladribine-based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

What's the purpose of the trial?

This is a prospective phase II clinical study planned to be conducted at the Medical College of Wisconsin (MCW). After meeting the study criteria and enrollment, patients will be treated with a cladribine based salvage regimen and followed at periodic intervals to determine the primary and secondary objectives.
Trial status

Accepting patients

Phase
Phase 2
Enrollment
90
Last Updated
3 months ago
Am I Eligible

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Cladribine is a chemotherapy medication approved for use in hairy cell leukemia, B-cell chronic lymphocytic leukemia, and multiple sclerosis. 
  • Cytarabine is an antineoplastic chemotherapy agent that is FDA approved to treat several different kinds of leukemia.
  • Granulocyte Colony-Stimulating Factor is a glycoprotein used to stimulate the bone marrow to help with granulocyte and stem cell production.
  • Mitoxantrone is an antineoplastic chemotherapy agent used in the treatment of several different kinds of cancer and multiple sclerosis.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

CLAG-M Regimen

Accepting patients

CLLDAC Regimen

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.